As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

The global artificial intelligence (AI) in drug discovery market is projected to reach USD 6.89 billion by 2029 from USD 1.86 ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

“This achievement is a testament to the strength and determination of the Timor-Leste people and the power of public-private partnerships, including the Mectizan Donation Program.” Thomas Breuer, ...

The US group's division has reported a pre-tax profit of $39.5m (£30.6m) for the 12 months to 31 January, 2024, according to ...

There’s no better time to be alive, only if we can learn to thrive amidst constant change and disruption” muses health tech ...

The Clorox Company (NYSE: CLX) announced a strategic partnership with Manufacture 2030, or M2030, to help Clorox's suppliers ...

Nature’s Bounty Co., NOW Foods, Pfizer Inc., Bayer AG, GlaxoSmithKline (GSK), GNC Holdings ... susceptible to bone and joint ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

The global glucosamine supplement market is projected to grow from USD 583.6 million in 2023 to USD 932.7 million by 2033, expanding at a CAGR of 4.8%, according to Future Market Insights. The rising ...